HD domain containing 3Genealiases: (ppGpp)ase · MESH1 · MYNRL15
Q-omics provides the consensus-scored HDDC3 profile across patient tissues and cancer cell-line models. HDDC3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, HDDC3 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, HDDC3 protein abundance shows 19,775 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight OV, BLCA, and PDAC as cancer lineages where HDDC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HDDC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HDDC3 survival associations across molecular data types. HDDC3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HDDC3 RNA expression–survival associations across cancer types. High HDDC3 expression shows unfavorable associations in LUAD, UVM, LAML and KIRP, but favorable associations in OV and UCEC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for HDDC3 RNA expression.
This table summarizes HDDC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for HDDC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HDDC3 shows lower tumor expression in THCA and higher tumor expression in BLCA, COAD, LIHC, KIRC and CHOL. The BLCA box plot shows higher HDDC3 RNA expression in tumor versus normal tissue (log2 FC = +0.764, t-test p = .001).
This table shows molecular features associated with HDDC3 in patient tissues and cancer cell lines. In patient samples, HDDC3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, HDDC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
